Athira Pharma, Inc. (ATHA) Misses Q3 EPS by 155c

Athira Pharma, Inc. (NASDAQ: ATHA) reported Q3 EPS of ($1.68), $1.55 worse than the analyst estimate of ($0.13).

For earnings history and earnings-related data on Athira Pharma, Inc. (ATHA) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• RBC Capital Downgrades Hermes International (RMS:FP) (HESAY) to Sector Perform
• Canaccord Starts Sunshine Silver Mining & Refining (SSMR) at Spec. Buy